FDA peptides: Kennedy reshapes advisory committee

United States: The US health authority FDA is at a turning point: While its own scientists warn against expanded access to unapproved peptides, Health Secretary Robert F. Kennedy Jr. has reshaped the responsible advisory committee - with members who partly sell peptide products themselves. The committee subsequently recommended easing restrictions on most of the reviewed peptides. This could fundamentally change the peptide market - and it also affects you if you are learning about peptides.

Peptides are short chains of amino acids that control a variety of signals in the body. Well-known examples are GLP-1 drugs such as semaglutide and tirzepatide, which regulate appetite as peptide hormones. However, many other peptides, such as BPC-157 or TB-500, are not approved as medications in the US and are often sold online as "research chemicals." The FDA scientists argue that there is insufficient evidence of safety and efficacy for these substances - and that it is not even clear exactly what chemicals are in the products.

The essentials at a glance

• FDA advisory panel reshuffle: Kennedy appointed six new members who themselves sold peptide products.
• Warning from FDA scientists: Before any easing of restrictions, evidence of safety and efficacy is lacking.
• Easing for six of seven peptides: The panel recommended fewer restrictions for most of the peptides reviewed.
• Production in compounding pharmacies: If restrictions are eased, these pharmacies could produce the peptides by prescription.
• Significance of the recommendation: The vote is not binding, but the FDA usually follows it.

What exactly are the FDA scientists demanding?

The FDA's career scientists have clearly spoken out against easing the restrictions. In internal statements and briefings, they recommend maintaining the current rules, which allow the production of these peptides in the US only for research purposes. Their reasoning: There is a lack of solid studies on benefits and risks. As early as 2023, FDA experts determined that the substances in question have no proven benefit and pose potential safety risks. One unnamed physician even spoke of an "extraordinary abuse of the advisory committee process."

How did Kennedy reshape the committee?

In the weeks before the hearing, Kennedy's office nominated eight new members for the advisory committee - six of them have sold peptide products themselves, some with health-related claims that have little scientific support. In addition, Republican Senator Bobby Harshbarger, a pharmacist, sits on the committee; his mother had urged Kennedy in writing to ease the restrictions. The Department of Health and Human Services emphasizes that all members underwent the usual ethics review. Critics such as cell biologist Paul Knoepfler from the University of California, however, speak of a "stacked" committee that could outvote the FDA staff.

What did the committee recommend?

At the two-day hearing in late July 2026, seven different peptide therapies were up for debate - none of them is an FDA-approved medication. The committee largely ignored the warnings of the FDA scientists and recommended by a narrow majority to ease restrictions on six of the seven peptides. Specifically, this concerns permission for specialized pharmacies (compounding pharmacies) to produce these peptides by prescription. Currently, they cannot be produced in the US, which drives many users to buy untested substances online - often with the note "for research purposes only."

What does this mean for the market?

If Kennedy implements the recommendation, it would be a major victory for the wellness and longevity industry, which would benefit significantly from expanded access. Compounding pharmacies and telemedicine companies are already preparing to offer prescriptions. At the same time, it would be a defeat for the FDA's safety and efficacy analysts. The final decision lies with the FDA - the committee's recommendation is not binding but is usually followed. For the market, this means: more legal offerings, but also more responsibility for consumers to check the quality and credibility of products.

What does this mean for you?

If you are interested in peptides, you should keep an eye on this development. An easing could make access easier, but it could also bring new risks - especially because the substances are still not approved as medications. I recommend informing yourself independently and, if you have questions about safety, using the Vendor Radar to check providers. The Peptide Library also helps you classify active ingredients and the evidence base. And if you are planning specific applications, you will find support for correct handling in the Injection Calculator.

Important: This article is for informational purposes only and does not replace medical or nutritional medical advice. No medical advice - for health questions, contact a professional.